NEWTON,
Mass., May 8, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company's senior management team will participate at the 2024
RBC Capital Markets Global Healthcare Conference in a fireside chat
on Wednesday, May 15 at 9:30 a.m. ET.
A live webcast of the fireside chat can be accessed under
"Events & Presentations" in the Investor section of the
Company's
website, http://investors.karyopharm.com/events-presentations,
and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a fundamental
mechanism of oncogenesis. Karyopharm's lead compound and
first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO®
(selinexor), is approved in the U.S. and marketed by the Company in
three oncology indications. It has also received regulatory
approvals in various indications in a growing number of ex-U.S.
territories and countries, including Europe and
the United Kingdom (as NEXPOVIO®) and China.
Karyopharm has a focused pipeline targeting indications in multiple
high unmet need cancers, including in multiple myeloma, endometrial
cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
For more information about our people, science and pipeline, please
visit www.karyopharm.com, and follow us on LinkedIn and on X
at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm
Therapeutics Inc. Any other trademarks referred to in this release
are the property of their respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-2024-rbc-capital-markets-global-healthcare-conference-302138529.html
SOURCE Karyopharm Therapeutics Inc.